Niapelf (Paliperidone)

Paliperidone, the active ingredient in Niapelf, is an atypical antipsychotic presented as an intramuscular injection for intramuscular use. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adult patients, helping to control psychotic symptoms and reduce relapse risk.

GNH USA supplies Niapelf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to European Union quality standards and providing reliable global distribution. Our network ensures timely delivery and regulatory compliance across markets.

Paliperidone is an atypical antipsychotic that modulates dopamine and serotonin pathways in psychotic disorders.

- Schizophrenia: reduces positive and negative symptoms and helps prevent relapse. - Schizoaffective disorder: stabilizes mood swings and psychotic features. - Maintenance therapy for schizophrenia: provides long‑term symptom control after acute stabilization.

Paliperidone may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Drowsiness or somnolence. - Weight gain: gradual increase. - Extrapyramidal symptoms: tremor, rigidity, or akathisia.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Orthostatic hypotension: marked drop in blood pressure upon standing. - Seizures: rare but possible.

When prescribing or handling Paliperidone, several safety considerations should be observed.

- Cardiovascular monitoring: assess for orthostatic hypotension and arrhythmias. - Metabolic assessment: monitor weight, glucose, and lipid levels regularly. - CNS effects: evaluate for sedation, dizziness, and extrapyramidal symptoms. - Pregnancy and lactation: use only if benefits outweigh potential risks; consult obstetric specialist. - Drug‑induced hyperprolactinemia: watch for menstrual disturbances or galactorrhea. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paliperidone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase paliperidone plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - QT‑prolonging agents (e.g., quinidine, sotalol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Other antipsychotics: additive central nervous system depression. - Antihypertensive drugs: may enhance orthostatic hypotension. - Alcohol or CNS depressants: increase sedation and dizziness.